What a buyer sees
PHARMAPAC HOLDINGS LIMITED
Activities of head offices · Craigavon · NI067358
156staff · FY2025
19years trading
—oldest owner on file
£971kcash at bank
Your turnover is on public record
filed£23Mfor the year to 2025
Unusual at this size, and it works in your favour: a buyer is reading your number rather than guessing at one.
What your filings show moving
Staff156
2021157 → 1562025
Cash at bank£971k
2021£1k → £971k2025
How you sit in your trade
slowest tenth typical fastest tenth youSales per employee£150,362in the middle half
£57,344£130,826£323,155
Debtor daysdays49in the middle half
2061109
Creditor daysdays33
82162
Stock daysdays60in the top quarter
730102
Each spread is companies in the same trade and size that did publish a turnover. Creditor days are shown but not marked: neither end of that one is plainly good.
What a buyer would ask 3
- The last accounts went in 12 months after year endThe allowance is nine. A buyer reads a late filing as a question about the finance function rather than about the trading.
- Stock days run high for your tradeYours is 60 against 30 for the middle of 138 comparable companies. That gap is working capital a buyer has to fund on day one, and it comes off the price.
- No website on file against the companyThe first thing anyone does with a company number is look for the business behind it. Finding nothing is its own answer.
What a buyer would like 1
- Headcount grew from 133 to 156Growth a buyer can verify without asking you for anything.
What the register says
Owners
Nobody recorded with significant control.
Directors
- 74since 2008
- 46since 2018
| Year to | Filed | Turnover | Staff | Cash |
|---|---|---|---|---|
| 2025-06-30 | 2026-06-30 | £23M | 156 | £971k |
| 2023-06-30 | — | not filed | 133 | £1k |
| 2022-06-30 | — | not filed | 137 | £1k |
| 2021-06-30 | — | not filed | 157 | £1k |
A rough bracket, and why it is only that
0.8–2× sales£19M£47M
The turnover range is fitted on UK companies that did file one. The multiple is a published sector average from Dutch mid-market deals, not from your own numbers and not from your own market. Treat this as the opening bracket of a conversation, not a valuation.